|
1
|
Jaaback K and Johnson N: Intraperitoneal
chemotherapy for the initial management of primary epithelial
ovarian cancer. Cochrane Database Syst Rev. 1:CD0053402006.
|
|
2
|
Mirza MR, Monk BJ, Herrstedt J, Oza AM,
Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I,
et al: ENGOT-OV16/NOVA investigators: Niraparib maintenance therapy
in platinum-sensitive, recurrent ovarian cancer. N Engl J Med.
375:2154–2164. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj
A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E,
Cruickshank D, et al: Ovarian cancer screening and mortality in the
UK collaborative trial of ovarian cancer screening (UKCTOCS): A
randomised controlled trial. Lancet. 387:945–956. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Oikonomopoulou K, Li L, Zheng Y, Simon I,
Wolfert RL, Valik D, Nekulova M, Simickova M, Frgala T and
Diamandis EP: Prediction of ovarian cancer prognosis and response
to chemotherapy by a serum-based multiparametric biomarker panel.
Br J Cancer. 99:1103–1113. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang H, Liu T, Zhang Z, Payne SH, Zhang
B, McDermott JE, Zhou JY, Petyuk VA, Chen L, Ray D, et al: CPTAC
investigators: Integrated proteogenomic characterization of human
high-grade serous ovarian cancer. Cell. 166:755–765. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wright AA, Bohlke K, Armstrong DK, Bookman
MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, et
al: Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian
cancer: Society of gynecologic oncology and American society of
clinical oncology clinical practice guideline. Gynecol Oncol.
143:3–15. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhao Z, Yang Y, Zeng Y and He M: A
microfluidic ExoSearch chip for multiplexed exosome detection
towards blood-based ovarian cancer diagnosis. Lab Chip. 16:489–496.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Strickland KC, Howitt BE, Shukla SA, Rodig
S, Ritterhouse LL, Liu JF, Garber JE, Chowdhury D, Wu CJ, D'Andrea
AD, et al: Association and prognostic significance of
BRCA1/2-mutation status with neoantigen load, number of
tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high
grade serous ovarian cancer. Oncotarget. 7:13587–13598. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Au Yeung CL, Co NN, Tsuruga T, Yeung TL,
Kwan SY, Leung CS, Li Y, Lu ES, Kwan K, Wong KK, et al: Exosomal
transfer of stroma-derived miR21 confers paclitaxel resistance in
ovarian cancer cells through targeting APAF1. Nat Commun.
7:111502016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bracken CP, Scott HS and Goodall GJ: A
network-biology perspective of microRNA function and dysfunction in
cancer. Nat Rev Genet. 17:719–732. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Christopher AF, Kaur RP, Kaur G, Kaur A,
Gupta V and Bansal P: MicroRNA therapeutics: Discovering novel
targets and developing specific therapy. Perspect Clin Res.
7:68–74. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li D, Wei Y, Wang D, Gao H and Liu K:
MicroRNA-26b suppresses the metastasis of non-small cell lung
cancer by targeting MIEN1 via NF-κB/MMP-9/VEGF pathways. Biochem
Biophys Res Commun. 472:465–470. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
John Clotaire DZ, Zhang B, Wei N, Gao R,
Zhao F, Wang Y, Lei M and Huang W: MiR-26b inhibits autophagy by
targeting ULK2 in prostate cancer cells. Biochem Biophys Res
Commun. 472:194–200. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Burges A and Schmalfeldt B: Ovarian
cancer: Diagnosis and treatment. Dtsch Arztebl Int. 108:635–641.
2011.PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wentzensen N, Poole EM, Trabert B, White
E, Arslan AA, Patel AV, Setiawan VW, Visvanathan K, Weiderpass E,
Adami HO, et al: Ovarian cancer risk factors by histologic subtype:
An analysis from the ovarian cancer cohort consortium. J Clin
Oncol. 34:2888–2898. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Romagnolo C, Leon AE, Fabricio ASC,
Taborelli M, Polesel J, Del Pup L, Steffan A, Cervo S, Ravaggi A,
Zanotti L, et al: HE4, CA125 and risk of ovarian malignancy
algorithm (ROMA) as diagnostic tools for ovarian cancer in patients
with a pelvic mass: An Italian multicenter study. Gynecol Oncol.
141:303–311. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Morgan RJ Jr, Armstrong DK, Alvarez RD,
Bakkum-Gamez JN, Behbakht K, Chen LM, Copeland L, Crispens MA,
DeRosa M, Dorigo O, et al: Ovarian Cancer, Version 1.2016, NCCN
Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw.
14:1134–1163. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Inamura K and Ishikawa Y: MicroRNA in lung
cancer: Novel biomarkers and potential tools for treatment. J Clin
Med. 5:362016. View Article : Google Scholar
|
|
21
|
Saadatpour L, Fadaee E, Fadaei S, Nassiri
Mansour R, Mohammadi M, Mousavi SM, Goodarzi M, Verdi J and Mirzaei
H: Glioblastoma: Exosome and microRNA as novel diagnosis
biomarkers. Cancer Gene Ther. 23:415–418. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li Z, Ma YY, Wang J, Zeng XF, Li R, Kang W
and Hao XK: Exosomal microRNA-141 is upregulated in the serum of
prostate cancer patients. Onco Targets Ther. 9:139–148.
2015.PubMed/NCBI
|
|
23
|
Sun C, Li S, Yang C, Xi Y, Wang L, Zhang F
and Li D: MicroRNA-187-3p mitigates non-small cell lung cancer
(NSCLC) development through down-regulation of BCL6. Biochem
Biophys Res Commun. 471:82–88. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rubiś P, Totoń-Żurańska J,
Wiśniowska-Śmiałek S, Holcman K, Kołton-Wróż M, Wołkow P, Wypasek
E, Natorska J, Rudnicka-Sosin L, Pawlak A, et al: Relations between
circulating microRNAs (miR-21, miR-26, miR-29, miR-30 and
miR-133a), extracellular matrix fibrosis and serum markers of
fibrosis in dilated cardiomyopathy. Int J Cardiol. 231:201–206.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li Y, Sun Z, Liu B, Shan Y, Zhao L and Jia
L: Tumor-suppressive miR-26a and miR-26b inhibit cell
aggressiveness by regulating FUT4 in colorectal cancer. Cell Death
Dis. 8:e28922017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shi L, Yin W, Zhang Z and Shi G:
Down-regulation of miR-26b induces cisplatin resistance in
nasopharyngeal carcinoma by repressing JAG1. FEBS Open Bio.
6:1211–1219. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu J, Tu F, Yao W, Li X, Xie Z, Liu H, Li
Q and Pan Z: Conserved miR-26b enhances ovarian granulosa cell
apoptosis through HAS2-HA-CD44-Caspase-3 pathway by targeting HAS2.
Sci Rep. 6:211972016. View Article : Google Scholar : PubMed/NCBI
|
